-
Mashup Score: 12
APCCC 2024, Radioligand Therapy, Dosing of Radioligand Therapy, Dosing of Radioligand Therapy in Special Situations And/or Toxicity, 177Lu-PSMA, VISION trial, Lu-PSMA therapy, Lu-PSMA I&T, ENZA-p trial, enzalutamide.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 11APCCC 2024: Patient Selection for Radioligand Therapy: How to Do It in Clinical Practice and How to Decide on the Number of Cycles. - 10 day(s) ago
APCCC 2024, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), Radioligand Therapy, FDG PET, VISION trial, TheraP trial, 68Ga-PSMA-11, “VISION-TheraP” gap, 177Lu-SPECT/CT imaging, 18F-FDG PET/CT, 177LuPSMA-I&T, PSMA uptake.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 37APCCC 2024: Hot Flushes – How Can We Help Our Patients? - 12 day(s) ago
APCCC 2024, prostate cancer, Hot Flushes, Hot Flushes from prostate cancer treatment, management of Hot Flushes, therapy recommendations for addressing hot flushes, PATCH trial.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 11
APCCC 2024, Brazilian Unified Healthcare System, cancer epidemiology in Latin America, LACOG 0218 HERCULES trial, REDEMPTED trial.
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Dealing with inequality – what can we learn from the Brazilian Unified Healthcare System. Presented by Fernando Maluf, MD, PhD, Hospital Israelita Albert Einstein. #APCCC24 Written coverage by @zklaassen_md @GACancerCenter @mcg_urology. > https://t.co/OllyxVBBMN @APCCC_Lugano https://t.co/wyq4teRw2E
-
-
Mashup Score: 6APCCC 2024: Dealing with Inequality – What Can We Learn from the Indian Healthcare System - 13 day(s) ago
APCCC 2024, Indian healthcare system, bhabhatron (telecobalt), Stereotactic body radiation therapy (SBRT), Stereotactic body radiation therapy in India, prostate radiotherapy, hypofractionation, inequality in indian healthcare system.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 6APCCC 2024: How Do We Modify the Diagnostic Pathway to Deal with Rising Rates of Prostate Cancer in Africa? - 13 day(s) ago
APCCC 2024, prostate cancer, prostate cancer in Africa, increase access to biopsy services in Africa, prostate cancer screening in Africa, rising rates of prostate cancer in Africa, access to prostate cancer screening in Africa, early prostate cancer diagnosis in Africa.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 66APCCC 2024: Testosterone Recovery After Stopping ADT – Who Is at Risk for Long-Term Non-Recovery? - 13 day(s) ago
Were you unable to attend APCCC 2024? Get all of the groundbreaking research, new guidelines, and the latest advances in urologic medicine you missed.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 8APCCC 2024: Hot Flushes – How Can We Help Our Patients? - 13 day(s) ago
APCCC 2024, prostate cancer, Hot Flushes, Hot Flushes from prostate cancer treatment, management of Hot Flushes, therapy recommendations for addressing hot flushes, PATCH trial.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 19APCCC 2024: Gynecomastia – How to Assess and Treat? - 13 day(s) ago
APCCC 2024, prostate cancer, Gynecomastia from prostate cancer treatment, androgen deprivation therapy (ADT), Gynecomastia from androgen deprivation therapy, androgen receptor pathway inhibitor (ARPI), Gynecomastia from androgen receptor pathway inhibitor, tamoxifen.
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 16APCCC 2024: The Importance of Bone Protection - 13 day(s) ago
APCCC 2024, prostate cancer, importance of bone protection in prostate cancer treatment, zoledronic acid decrease the risk of fracture-related hospitalizations in high-risk M1 mHSPC, Fracture-related hospitalizations in de novo advanced or metastatic hormone-sensitive prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
Dosing of radioligand therapy in special situations and/or toxicity. Presentation by @drlouiseemmett @SVHSydney. #APCCC24 written coverage by @RKSayyid @UofT on UroToday > https://t.co/3aburRXnQK @APCCC_Lugano https://t.co/EyglGTl3WZ